NanoPhoria Bioscience is a preclinical-stage biotechnology company pioneering the next generation of cardiovascular treatments through an innovative inhaled, Nano-in-Micro delivery platform
NanoPhoria Bioscience is a preclinical-stage biotechnology company pioneering the next generation of cardiovascular treatments through an innovative inhaled, Nano-in-Micro delivery platform. The company focuses on transforming therapeutic delivery for patients with cardiovascular conditions, particularly targeting heart failure with reduced ejection fraction (HFrEF).